Preclinical Evaluation of Antiangiogenic Thrombospondin-1 Peptide Mimetics, ABT-526 and ABT-510, in Companion Dogs With Naturally Occurring Cancers

Clinical Cancer Research- United States

doi 10.1158/1078-0432.ccr-06-0109

Full Text

Abstract

Available in

Date

Authors

Publisher

American Association for Cancer Research (AACR)

Related search

A Phase 1 Trial of ABT-510 Concurrent With Standard Chemoradiation for Patients With Newly Diagnosed Glioblastoma

Archives of Neurology
2010English

BCL-xL-Inhibitory BH3 Mimetics (ABT-737 or ABT-263) and the Modulation of Cytosolic Calcium Flux and Platelet Function

Blood
BiochemistryImmunologyCell BiologyHematology
2012English

Comparison of Putative BH3 Mimetics AT-101, HA14-1, Sabutoclax and TW-37 With ABT-737 in Platelets

Platelets
MedicineHematology
2020English

Human Pluripotent Stem Cells and Derived Neuroprogenitors Display Differential Degrees of Susceptibility to BH3 Mimetics ABT-263, WEHI-539 and ABT-199

PLoS ONE
Multidisciplinary
2016English

Evaluation ofClostridium Novyi–NT Spores in Dogs With Naturally Occurring Tumors

American Journal of Veterinary Research
MedicineVeterinary
2012English

Naturally Occurring Cancers in Pet Dogs as Pre-Clinical Models for Cancer Immunotherapy

Cancer Immunology, Immunotherapy
Cancer ResearchMedicineOncologyAllergyImmunology
2019English

Computed Tomography Imaging of Solid Tumors Using a Liposomal-Iodine Contrast Agent in Companion Dogs With Naturally Occurring Cancer

PLoS ONE
Multidisciplinary
2016English

Abt-Garrison History of Pediatrics

BMJ
1965English

Molecular Basis of Antiangiogenic Thrombospondin-1 Type 1 Repeat Domain Interactions With CD36

Arteriosclerosis, Thrombosis, and Vascular Biology
Cardiovascular MedicineCardiology
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy